Tvardi Therapeutics, Inc. (TVRD) — 10-Q Filings
All 10-Q filings from Tvardi Therapeutics, Inc.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 8, 2026
-
Tvardi's Cash Infusion Post-Merger Masks Deepening Burn Rate
— Nov 13, 2025 Risk: high
Tvardi Therapeutics, Inc. (TVRD) reported a net loss of $5.5 million for the three months ended September 30, 2025, and a net loss of $10.9 million for the nine -
Tvardi Swings to Q2 Profit on Merger Boost, Cash Dips
— Aug 14, 2025 Risk: high
Tvardi Therapeutics, Inc. (TVRD) reported a net income of $4.167 million for the three months ended June 30, 2025, a significant improvement from a net loss of -
Tvardi Therapeutics Files Q1 2025 10-Q
— May 13, 2025 Risk: medium
Tvardi Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Cara Therapeutics, Inc., is in the pharmaceutical -
Cara Therapeutics Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Cara Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business ope -
Cara Therapeutics Files Q2 2024 10-Q
— Aug 14, 2024 Risk: medium
Cara Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quar -
Cara Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: low
Cara Therapeutics, Inc. (TVRD) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Cara Therapeutics, Inc. reported financial results for the quarter
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX